Cargando…
Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885320/ https://www.ncbi.nlm.nih.gov/pubmed/33504661 http://dx.doi.org/10.1128/mSphere.01026-20 |
_version_ | 1783651580639182848 |
---|---|
author | Teo, Jocelyn Qi-Min Lim, Jie Chong Tang, Cheng Yee Lee, Shannon Jing-Yi Tan, Si Hui Sim, James Heng-Chiak Ong, Rick Twee-Hee Kwa, Andrea Lay-Hoon |
author_facet | Teo, Jocelyn Qi-Min Lim, Jie Chong Tang, Cheng Yee Lee, Shannon Jing-Yi Tan, Si Hui Sim, James Heng-Chiak Ong, Rick Twee-Hee Kwa, Andrea Lay-Hoon |
author_sort | Teo, Jocelyn Qi-Min |
collection | PubMed |
description | This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired β-lactamases, especially metallo-β-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by β-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents. IMPORTANCE Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β-lactam/β-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and β-lactamase inhibitors. WGS proved to be a useful tool to understand the P. aeruginosa resistome and its contribution to emerging resistance in novel antimicrobial agents. |
format | Online Article Text |
id | pubmed-7885320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-78853202021-02-19 Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa Teo, Jocelyn Qi-Min Lim, Jie Chong Tang, Cheng Yee Lee, Shannon Jing-Yi Tan, Si Hui Sim, James Heng-Chiak Ong, Rick Twee-Hee Kwa, Andrea Lay-Hoon mSphere Research Article This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired β-lactamases, especially metallo-β-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by β-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents. IMPORTANCE Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β-lactam/β-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and β-lactamase inhibitors. WGS proved to be a useful tool to understand the P. aeruginosa resistome and its contribution to emerging resistance in novel antimicrobial agents. American Society for Microbiology 2021-01-27 /pmc/articles/PMC7885320/ /pubmed/33504661 http://dx.doi.org/10.1128/mSphere.01026-20 Text en Copyright © 2021 Teo et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Teo, Jocelyn Qi-Min Lim, Jie Chong Tang, Cheng Yee Lee, Shannon Jing-Yi Tan, Si Hui Sim, James Heng-Chiak Ong, Rick Twee-Hee Kwa, Andrea Lay-Hoon Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa |
title | Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa |
title_full | Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa |
title_fullStr | Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa |
title_full_unstemmed | Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa |
title_short | Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa |
title_sort | ceftolozane/tazobactam resistance and mechanisms in carbapenem-nonsusceptible pseudomonas aeruginosa |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885320/ https://www.ncbi.nlm.nih.gov/pubmed/33504661 http://dx.doi.org/10.1128/mSphere.01026-20 |
work_keys_str_mv | AT teojocelynqimin ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa AT limjiechong ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa AT tangchengyee ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa AT leeshannonjingyi ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa AT tansihui ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa AT simjameshengchiak ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa AT ongricktweehee ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa AT kwaandrealayhoon ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa |